Restoring TGFβ function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation

被引：0
|
作者：
Janindra Warusavitarne
Fiona McDougall
Keshani de Silva
Rebecca Barnetson
Marinella Messina
Bruce G. Robinson
Margaret Schnitzler
机构：
[1] Royal North Shore Hospital and University of Sydney,Department of Cancer Genetics, Kolling Institute of Medical Research
[2] Royal North Shore Hospital,Department of Anatomical Pathology, PaLMS
来源：
International Journal of Colorectal Disease | 2009年 / 24卷
关键词：
Microsatellite instability; TGFβ; Metastasis; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：139 / 144
页数：5
相关论文
共 50 条
  • [31] TGF-B AND pSMAD3 Co-expression in the Tumor Associated Macrophages is Associated with Lymph Node Metastasis, Lymphovascular invasion and MSI-H Status in Primary Colorectal Carcinoma
    Jadhav, Akshaya
    Khanduri, Isha
    Zhang, Shanyu
    Mejia, Alicia
    Soto, Luisa Solis
    Tong, Zhimin
    Wistuba, Ignacio
    Parra, Edwin
    Kopetz, Scott
    Maru, Dipen
    LABORATORY INVESTIGATION, 2024, 104 (03) : S721 - S722
  • [32] Decreased TGF-βRII expression causes disruption of the TGF-β signal pathway resulting in decreased CDK2-AP1 expression in microsatellite unstable (MSI) human colorectal cancer (CRC)
    Shin, J.
    Yuan, Z.
    Sreeramoju, P.
    Fordyce, K.
    Lai, V.
    White, N.
    Weber, T. K.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 21 - 21
  • [33] Development of a novel RNA-based microsatellite stable predictive response signature (MSS-PRS) to identify MSS colorectal cancer (CRC) patients with a microsatellite instability-high (MSI-H) molecular phenotype
    Pappan, Kirk
    Mayhew, Gregory
    Shepherd, Jonathan
    Guo, Yuelong
    Beebe, Kirk
    Eisner, Joel
    Milburn, Michael
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC).
    Salem, Mohamed E.
    Andre, Thierry
    El-Refai, Sherif Mohamed
    Kopetz, Scott
    Tabernero, Josep
    Sinicrope, Frank A.
    Tie, Jeanne
    George, Thomas J.
    VanCutsem, Eric
    Mauer, Elizabeth
    Lonardi, Sara
    Overman, Michael J.
    Foureau, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer.
    Larsen, Stein G.
    Dueland, Svein
    Goscinski, M.
    Steigen, Sonja
    Hofsli, Eva
    Flatmark, Kjersti
    Sorbye, Halfdan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] COMPARISON OF REAL-WORLD LATER-LINE TREATMENT OUTCOMES IN PATIENTS WITH MICROSATELLITE-INSTABILITY HIGH (MSI-H) VERSUS MICROSATELLITE-STABLE (MSS) METASTATIC COLORECTAL CANCER (MCRC) IN THE UNITED STATES (US)
    Dixon, M.
    Gu, J.
    VALUE IN HEALTH, 2022, 25 (07) : S313 - S314
  • [37] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study
    Overman, M. J.
    Kopetz, S.
    Lonardi, S.
    McDermott, R.
    Leone, F.
    Leach, J.
    Lenz, H-J.
    Hendlisz, A.
    Morse, M.
    Garcia-Alfonso, P.
    Desai, J.
    Hill, A.
    Moss, R. A.
    Goldberg, M. V.
    Lin, C-S.
    Tang, H.
    Andre, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
12345